Spero Therapeutics, Inc. (SPRO)
After hours:
| Previous close | 1.4400 |
| Open | 1.5700 |
| Bid | 1.4300 x 1800 |
| Ask | 1.4300 x 900 |
| Day's range | 1.4100 - 1.6500 |
| 52-week range | 0.6800 - 7.8700 |
| Volume | |
| Avg. volume | 551,974 |
| Market cap | 75.075M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.0400 |
| Earnings date | 15 May 2023 - 19 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.33 |
- Simply Wall St.
Spero Therapeutics (NASDAQ:SPRO) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on March 23, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 95,000 restricted stock unit awards (RSUs) to f
- Zacks
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
